©The Author(s) 2025.
World J Diabetes. Dec 15, 2025; 16(12): 111963
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.111963
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.111963
Figure 1 Overview of the study design in our Mendelian randomization and colocalization study.
DN: Diabetic neuropathy; UKB-PPP: United Kingdom biobank pharma proteomics project; eQTL: Expression quantitative trait loci; GTEx: Genotype-tissue expression; GWAS: Genome-wide association studies; MR: Mendelian randomization; SMR: Summary-data-based Mendelian randomization; FDR: False discovery rate; GO: Gene Ontology; Cis-pQTL: Cis-protein quantitative trait loci; HEIDI: Heterogeneity dependency tool; PheWAS: Phenome-Wide Association Study.
- Citation: Ding XF, Dang X, Lin S. Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches. World J Diabetes 2025; 16(12): 111963
- URL: https://www.wjgnet.com/1948-9358/full/v16/i12/111963.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i12.111963